Another Recommendation On Wall Street for Advanced Accelerator Applications (NASDAQ:AAAP). This time with a $32 Share Target Price

Share

Why Has Citigroup Given Advanced Accelerator Applications (NASDAQ:AAAP) a $32 Price Target

Analysts at Citigroup launched coverage on shares of Advanced Accelerator Applications (NASDAQ:AAAP) in recent note released on 7 December. The firm set “Buy” rating on the $1.02B market cap company.

Approximately 3,262 shares of stock traded hands. Advanced Accelerator Application SA(ADR) (NASDAQ:AAAP) has risen 6.00% since November 7, 2015 and is uptrending. It has outperformed by 7.08% the S&P500.

Another Recommendation On Wall Street for Advanced Accelerator Applications (NASDAQ:AAAP). This time with a $32 Share Target Price

Advanced Accelerator Applications SA is a radiopharmaceutical firm that develops, produces and sells molecular nuclear medicine , diagnostic and therapeutic products. The company has a market cap of $1.02 billion. The Company’s lead therapeutic candidate, Lutathera, is being developed for the treatment of midgut neuroendocrine tumors (NETs). It currently has negative earnings. The Firm has a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products.

According to Zacks Investment Research, “Advanced Accelerator Applications S.A. is a radiopharmaceutical company. The company, develops, produces and commercializes molecular nuclear medicine diagnostic and therapeutic products. Its products in clinical development include Lutathera, Somakit and Annexin V-128. The company’s commercial products include Gluscan /Gluscan 500/Barnascan(R), IASOflu(R), IASOdopa(R), IASOcholine(R), MIBITEC/Adamibi and Leukokit(R). It operates primarily in France, Italy, the United Kingdom, Spain, Portugal, Israel, Switzerland, Germany and Canada. Advanced Accelerator Applications S.A. is headquartered in Saint Genis Pouilly, France.” Get a free copy of the Zacks research report on Advanced Accelerator Application SA(ADR) (AAAP).

COMMENTS: